Private Equity

Trump's drug cost concern an opportunity for Indian firms

"If controlling cost of drugs is a priority for the new administration, US cannot write off Indian pharmaceutical products. At the price we offer, US companies cannot produce them in that country,".

Vrinda Mathur
Partner, Grant Thornton India LLP

This article apeared in My Digital FC on 23rd January, 2017.